Oslo Cancer Cluster gathers the relevant stakeholders, is an active facilitator and provides a platform for advancing the development and clinical implementation of precision oncology.
Cancer is a disease encompassing hundreds of different tumor types characterized by different genetic mutations and responding differently to the increasing number of therapies, including targeted therapies, immuno-therapies and treatment combinations. Oncology is spearheading precision medicine with the ultimate goal to provide the right treatment to the right patient at the right time. The implementation of precision oncology requires broad collaboration among researchers, clinicians, IT and technical experts and partnerships between academia and industry.
International projects
- Collaboration on precision cancer screening between the Norwegian Cancer Registry and the Lawrence Livermore Laboratories, see details here.
- EU Horizon 2020 project: PERMIDES (Personalized Medicine Innovation through Digital Enterprise Solutions), 2016-2018
- EU Horizon 2020 Project: Digi-B-Cube (Digital Enterprise Innovations for Bioimaging, Biosensing and Biobanking Industries), 2019-2022
National initiatives
Our participation in national initiatives facilitating precision medicine:
- National Expert Committee on Health Data (link in Norwegian)
Workshops and meetings
Oslo Cancer Cluster organizes discussions and workshops connecting national and international experts to advance the implementation of a precision oncology infrastructure and to stimulate public-private exchange and collaboration.
- Cancer Crosslinks 2019 with international experts and “Call for Action: Next Wave of Precision Oncology for Patients in Norway” (January 2019)
- Partner for Nordic Precision Medicine Forum in Stockholm (March 2019)
- Workshop with David Thomas, CEO Australian Genomic Cancer Medicine Center in Oslo (May 2019)
- Partner of EHiN in Oslo (12-13 November 2019)
- Partner for Inaugural Cancer Precision Medicine Forum in Berlin (2-3 December 2019)
The National Program for Personalized Cancer Medicine with the aim to build a national cancer diagnostics platform based on next generation sequencing (2011-2018)
With reference to the UK’s Stratified Medicine Initiative, Pfizer Norway and Oslo Cancer Cluster kicked off a Norwegian initiative in 2011 which resulted in the formation of the Norwegian Cancer Genomics Consortium (NCGC). The interdisciplinary consortium gathered university hospitals and research teams from all Norwegian health regions. Oslo Cancer Cluster actively contributed by disseminating the results and by involving private partners. The program attracted total funding of NOK 75M from the Norwegian Research Council. The final report can be downloaded here (in Norwegian).
